



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/571,469	03/13/2006	Frank Mattner	286808US0PCT	6417
22850 7590 06/17/2009 OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, P.C. 1940 DUKE STREET ALEXANDRIA, VA 22314			EXAMINER KOLKER, DANIEL E	
			ART UNIT 1649	PAPER NUMBER
			NOTIFICATION DATE 06/17/2009	DELIVERY MODE ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com  
oblonpat@oblon.com  
jgardner@oblon.com

<b>Office Action Summary</b>	<b>Application No.</b> 10/571,469	<b>Applicant(s)</b> MATTNER ET AL.	
	<b>Examiner</b> DANIEL KOLKER	<b>Art Unit</b> 1649	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 18 February 2009.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 5-11 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 5-11 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 13 March 2006 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |                                                                                      |                                                                   |
|--------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____                                                          | 6) <input type="checkbox"/> Other: _____                          |

Art Unit: 1649

### **DETAILED ACTION**

1. The remarks and amendments filed 18 February 2009 have been entered. Claims 1 - 4 are canceled; claims 5 - 11 are pending and under examination.

#### ***Withdrawn Rejections and Objections***

2. All rejections and objections of previous claim 4 are moot as the claim has been canceled by amendment. The rejections under 35 USC 102(e) have been overcome by amendment. While the references by Frangione, including provisional application 60/434736, each teach methods of removing A $\beta$  from patients with Alzheimer's by passing the blood over a column containing an A $\beta$ -binding molecule, the present claims are now limited to anti-APP antibodies. While such antibodies are taught in the PCT by Frangione, they are not explicitly taught in the provisional application. Note original claim 4 was drawn to use of an apheresis device comprising a receptor (of essentially any structure) that binds APP, whereas the present claims are now drawn to methods of using apheresis devices comprising an antibody.

#### ***Rejections and Objections Necessitated by Amendment***

##### ***Claim Objections***

3. Claim 5 is objected to because of the following informalities: it uses the abbreviation APP without first spelling out the name of the protein. The protein is clearly amyloid precursor protein, so the claim is not indefinite. However for the sake of clarity, appropriate correction is required.

4. Claim 11 is objected to because of the following informalities: there is no period at the end of the claim. Appropriate correction is required.

##### ***Claim Rejections - 35 USC § 103***

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various

Art Unit: 1649

claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 5 - 8 and 10-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over DeMattos 2001 (Proc Natl Acad Sci USA 98:8850-8855) in view of Sen 2003 (Anal. Chem. 75:1196-1202; note first page of the enclosed printout indicates that the reference was published electronically on 31 January 2003).

DeMattos teaches that peripheral administration of an antibody against A $\beta$ , namely antibody m266, leads to a 1000-fold increase in the amount of A $\beta$  in the bloodstream and a decrease in the amount of this toxic protein in the brains of mice. See for example abstract. DeMattos hypothesizes that peripherally administering the antibody alters the equilibrium of A $\beta$  between brain and plasma, suggesting that after circulating Ab is sequestered by the blood, more A $\beta$  exits the brain. The m266 antibody used binds to an epitope within residues 13-28 of A $\beta$  (DeMattos, p. 8851, first paragraph of the Results and Discussion section), so it will bind to both A $\beta$ 40 and A $\beta$ 42, as recited in claims 6 - 8. The PDAPP mice can be construed as both suffering from AD as recited in claim 10 and at risk of AD as recited in claim 11. They are suffering from AD in that they have A $\beta$  deposits similar to those seen in human Alzheimer's patients, since they carry a nucleic acid that encodes an A $\beta$  mutation seen in human Alzheimer's disease. They can also be considered to be at risk for AD, since they are genetically susceptible to this condition; see p. 8851, paragraph spanning the two columns. DeMattos suggests that antibodies against A $\beta$  can be used to draw A $\beta$  out of the brain and clear it from the patient, which would be therapeutic in patients with AD; see p. 8854 last paragraph. However while DeMattos suggests using antibodies against A $\beta$  to remove this protein from the brain and into the blood, the reference does not explicitly teach contacting the blood or plasma flow of a patient with an apheresis device that has the anti-A $\beta$  antibodies attached to the surface of a solid carrier as recited in claim 5.

Sen teaches that contacting an affinity column wherein antibodies against A $\beta$  are coupled to a solid surface with a sample comprising A $\beta$  peptide is sufficient to remove the peptide from the sample. See for example paragraph spanning pp. 1199 - 1200, which

Art Unit: 1649

indicates that the column is able to remove both A $\beta$ 40 and A $\beta$ 42 from the sample, as well as p. 1197 second column first complete paragraph for directions on how to couple the antibody to the column, and p. 1198 Figure 1 which shows a picture representing the apparatus. Note that the apparatus is able to detect both A $\beta$ 40 and A $\beta$ 42 from human CSF samples (p. 1200 second column). Given the expansive definition of “apheresis device” at p. 10 final sentence of the present specification, this immunoaffinity column can be considered to be an apheresis device as recited in claim 5. However Sen does not teach contacting blood or plasma flow from patients with AD with the device.

6. Claims 5 - 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over DeMattos in view of Sen as applied to claims 5 - 8 and 10 - 11 above, and further in view of Boos (U.S. Patent 5,679,775, issued 21 October 1997).

The reasons why claims 5 - 8 and 10 - 11 are obvious over DeMattos in view of Sen are set forth above. While Sen teaches a column, which fits the definition of an apheresis device set forth in the specification, and is clearly suitable for removing A $\beta$  from biological fluids, the reference does not explicitly teach a sterile pyrogen-free column as recited in claim 9.

Boos teaches sterile pyrogen-free columns for apheresis. See Example 1 spanning columns 6 - 7. The reference teaches that the columns can be used to remove disease related proteins from human blood or plasma; see column 6 lines 17 - 42. However Boos does not teach sterile pyrogen-free apheresis devices comprising antibodies that bind A $\beta$  or APP.

It would have been obvious to one of ordinary skill in the art to use sterile pyrogen-free columns as taught by Boos in the methods rendered obvious by DeMattos in view of Sen, thereby arriving at the invention of claim 9. The motivation to do so would be to use a device that would be less likely to infect patients, as sterile pyrogen-free materials would pose less of a risk of infection than the laboratory columns taught by Sen.

### ***Double Patenting***

7. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined

Art Unit: 1649

application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 5 - 11 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 22 – 27 of copending Application No. 11/571970. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims in the '970 application are specific as they require an additional step (administration of an agent) beyond the step of apheresis as claimed herein. The instant claims are generic, as they require only the step of using the apheresis device, which also appears in independent claim 22 of the '970 application. As the claims in the '970 application are species, they would anticipate the instant claims 5 - 11. Note that at p. 11 of the specification of the '970 application, anti-A $\beta$  antibodies are indicated to be preferred components of the apheresis device, and that sterile pyrogen-free columns are preferred.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Applicant did not traverse the examiner's rejection for obviousness-type double-patenting, but requested withdrawal of the rejection assuming the claims were otherwise allowable. As set forth above, the claims are not allowable, so this rejection stands.

Art Unit: 1649

**Conclusion**

8. No claim is allowed.

9. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIEL KOLKER whose telephone number is (571)272-3181. The examiner can normally be reached on Mon - Fri 8:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Stucker can be reached on (571) 272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Daniel E. Kolker/

Primary Examiner, Art Unit 1649

June 12, 2009